Discussion:
EPIDEMIOLOGY
Since the onset of the COVID-19 pandemic in December of 2019 in Wuhan,
China, there have been multiple reports about pediatric cases. On
January 10, 2020, a 10-year-old girl was identified as part of a family
cluster that had traveled to Wuhan2.
Several case series of hospitalized children have subsequently been
published (Table 2).
Sun et al reported10 on 8 children, aged 2 months to
15 years, who had severe disease requiring ICU admission. One of them
had acute lymphocytic leukemia and concomitant influenza infection,
while the remaining 7 were apparently previously healthy. There were no
deaths in this cohort at the time of reporting. Larger studies looked at
non-hospitalized children: in a study of 171 infected children,
identified mostly through contact tracing, 39 were asymptomatic (12 of
whom had radiologically confirmed pneumonia), and 3 required intensive
care, all of whom had preexisting morbidities11. An
epidemiologic study12 identified 2135 pediatric
patients with COVID-19, of which 55.4% had no or mild symptoms, 5.3%
had severe disease, defined as respiratory symptoms with hypoxia, and
0.6% were critically ill.
As for disease in infants, Wei et al13 reported on 10
patients with SARS-CoV-2 infection, 3 to 11-month-old, none of whom had
severe disease.
Most studies of pregnant women infected with SARS-CoV-2 showed no
symptoms and no evidence of infection in their neonates and
placentas14-17, except for one study where few
neonates had mild symptoms, with the virus isolated
briefly18. One series followed 10 newborns to 9
infected mothers, of which six developed symptoms, 2 became critically
ill and one died. All of them however tested negative for the
virus19.
With the spread of COVID-19 outside China, more case series were
reported: a study from Madrid, Spain20 identified 41
patients 0 to 15-year-old, of which 25 required hospitalization and 4
intensive care. A study from Italy21 reviewed 100
children, aged 0 to 17 years, presenting to emergency units with
SARS-CoV-2 infection. Of these, 21 patients had no symptoms. Nine
patients (6 with various comorbidities) required respiratory support,
ranging from oxygen supplementation to mechanical ventilation. All of
them recovered. In the New York City area, another hotbed of SARS-CoV-2
infection, of 5700 hospitalized patients, 32 were 18-year-old or
younger, 2 of which required intensive care, and none assisted
ventilation. All of them survived22.
In early April, The US CDC website23 reported 2,572
pediatric cases among a total of 149,082 SARS-CoV-2 infected patients
(1.7%). Around 60% of them were older than 10 years. Information on
hospitalization status was available on only 745 children (29%). Of
these, 20% were admitted to the hospital, 2% to the ICU. Underlying
conditions were identified in 13%, mostly chronic lung disease,
cardiovascular disease and immunosuppression. Three pediatric fatalities
were reported, but COVID-19 was not confirmed as the cause of death.
CLINICAL PRESENTATION
Clinically, children with COVID-19 could be asymptomatic, or they could
have nonspecific symptoms like low grade fever, sore throat, cough,
myalgias and fatigue that can progress into respiratory distress and
failure. Gastrointestinal symptoms like nausea, vomiting, diarrhea and
abdominal pain have also been reported. Two infants presented with
isolated fever and were found to be SARS-CoV-2 positive on sepsis work
up24. In the areas heavily affected by COVID-19, a
relatively large number of children are now being seen with a
“pediatric multisystem inflammatory syndrome”, having hypotension,
pneumonitis, occasionally myocarditis, coronary artery dilatation, acute
kidney injury and neurologic symptoms in addition to the known features
of Kawasaki disease (persistent fever, conjunctivitis, rash,
lymphadenopathy, swelling of the hands and feet)25-26.
Some of these children have tested positive for SARS-CoV-2. Of note, an
association between Kawasaki disease and coronaviruses has been
previously reported27.
LABORATORY FINDINGS
Laboratory findings are nonspecific. Compared to adults, possibly
because of their milder disease, pediatric patients with COVID-19 did
not show consistent neutrophilia or lymphopenia. Increase in C-reactive
protein and procalcitonin have been reported in some
cases28, as well as elevation in transaminases and
creatine-phosphokinase. The virus is identified by PCR in nasal
secretions, throat swabs, urine and stools. There has been reports of
prolonged viral shedding in stools in infants and young
children29-31, which may increase the risk of viral
spread. Children with the pediatric multisystem inflammatory syndrome
have shown a florid inflammatory response, with elevation of all
inflammatory markers, lymphopenia and occasionally coagulopathy.
RADIOLOGICAL FINDINGS
Radiologically, ground glass opacities were identified on computer
tomography of the chest. Compared to adults, these opacities tend to be
more localized in pediatric patients, described mostly in the peripheral
and posterior lung fields with lower attenuation and less lobular
involvement. Less common findings included consolidations with
surrounding halo signs or interlobular septa
thickening32-33. Plain chest radiography had a limited
role because it may not show the ground glass opacities. The radiologic
findings however are not specific nor sensitive, being sometimes present
in asymptomatic children and absent in symptomatic ones. Because of the
risk of radiation in this vulnerable population, imaging studies,
particularly CT scans should be ordered with caution.
TREATMENT
Various medications have been used to treat pediatric patients with
COVID-19. These have included nebulized interferon-α2b, the antivirals
lopinavir/litonavir, oseltamivir, umifenovir (Arbidol), ribavirin,
remdesivir, as well as chloroquine and hydroxychloroquine, azithromycin,
intravenous gamma globulins, steroids, tocilizumab (an interleukin-6
receptor antagonist) and others. An expert panel has recently issued a
“Multicenter initial guidance on use of antivirals for children with
COVID-19/SARS-CoV-2”34. Based on the available
evidence it recommends only supportive care for symptomatic children.
For those children who are critically ill, remdesivir is the preferred
antiviral agent, with hydroxychloroquine as an alternative for patients
who are not candidates for treatment with remdesivir. The Pediatric
Infectious Diseases Society has endorsed this statement.
WHY IS THIS DISEASE MILDER IN CHILDREN THAN ADULT?
It is not clear why COVID-19 is less severe in children than in adults.
This could be related to the presence in the children’s airways of other
respiratory viruses that interact and compete with the growth of
SARS-CoV235. Other hypotheses mention the non-specific
immunity that could be induced by widespread vaccination, with
BCG36, hepatitis A37 and oral polio
vaccines as examples, and the different inflammatory response in
children: a prospective study looking at age-dependent differences in
host response to lung injury found that the levels of interleukins 6 and
10, myeloperoxidase and p-selectins, which contribute to the cytokine
storm leading to severe disease, increased with age in the
bronchoalveolar lavage of ARDS patients38. The
relative upregulation in children of the ACE2
receptor39-40, which is the entryway of the virus into
the respiratory epithelial cells has also been proposed as a mechanism,
as studies in animal models and patients with RSV have shown that lung
pathology increased on downregulation of this receptor which was
restored by supplemental recombinant ACE241.
We also are suggesting two new hypotheses that can explain this
phenomenon. The first is related to the nature of the virus itself.
Different human coronaviruses behave differently based on the age of the
infected patients42. Human Coronavirus (HCoV)-OC43 and
HCoV-NL63 are more common in infants compared to HCoV-229E and
HCoV-HKU1. This same pattern has been documented with the other Corona
viruses that caused previous outbreaks, SARS-CoV34 and
MERS-CoV43. Also SARS-CoV caused up to 50%
mortalities in patients with underlying medical conditions and in
elderly but no mortality in patients younger than 24 years of age. On
the other hand, SARS-CoV2 has about 70% amino acid similarity with
SARS-CoV and it uses ACE2 as receptor44. With these
similarities, there is high probability that SARS-CoV2 is just acting
like SARS-CoV and it is less pathogenic in children. Our second theory
is related to the host. We know that higher viral load lead to a more
severe infection45-46. Based on the lung physiology,
breathing patterns and tidal volumes are different with ages. A healthy
1-year-old child has an average tidal volume of 60 mL and breaths
28-46/min, his total ventilation is 1,680-2,760 mL/min. A healthy
10-year-old child has a tidal volume of 190 mL, and breaths 16-22/min
his total ventilation is 3,000-4,000 mL/min. A healthy adult has a tidal
volume of 500 mL and breaths 12-15/min, his total ventilation is
6,000-7,500 mL/min47. If the viral load is directly
related to the inhaled volume of infected air, we can assume that
children with lower ventilation are inhaling lower viral load leading to
a milder disease.